Item 8.01 Other Events.

On January 30, 2020, Kezar Life Sciences, Inc. (the "Company") filed with the Securities and Exchange Commission (the "SEC") a preliminary prospectus supplement in connection with a proposed public offering of shares of the Company's common stock, par value $0.001 per share ("Common Stock"), and pre-funded warrants to purchase shares of its Common Stock. The preliminary prospectus supplement contains an updated description of certain aspects of the Company's business and certain risk factors. Accordingly, the Company is filing this information with this Current Report on Form 8-K for the purpose of supplementing and updating disclosures contained in the Company's prior filings with the SEC, including those discussed under the heading "Item 1A. Risk Factors," in the Company's most recent Annual Report on Form 10-K for the ended December 31, 2018, filed with the SEC on March 26, 2019. The updated disclosures are filed herewith as Exhibit 99.1 and are incorporated herein by reference.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



                   Exhibit   Description

                   99.1        Updated Company Disclosures.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses